Assertion Supported
Kidron: China deal pays Oramed $50M and 10% royalties, implying $1B valuation
“They're paying us fifty million dollars and 10% royalties, and they've been investing hundreds of millions of dollars into the facility of the building in China, and China is five percent of the global market of diabetes, so the value that they gave us, this f…”
Opinion
Kidron: US public markets hold a bias against China-derived deals
“So I think there's a little bit of a bias in the United States about anything which is China derived.”
Prediction Open · timeframe Oct 2023
Kidron: Oramed will probably enter the Chinese market before the US
“And with the Chinese FDA, we're probably going to get to the market even before the United States.”
Prediction Didn’t hold up
Kidron: Oramed will have 90-day oral insulin trial results by August 2019
“And in about 10 months from now, we're going to have the most important milestone in our history. We're going to have the result of a ninety-day trial when we administer oral insulin, and that's going to be a very, or the most clear-cut indication as to the va…”
Opinion
Kidron: Oral delivery of proven drugs lowers risk versus novel chemicals
“Here, what we do is we're taking insulin that has been around for a long time, and we know that it works, and we have the ability to deliver it orally instead of an injection that we already proved in principle that that works. So that's why I think while ther…”
Disclosure
Kidron: Future Oramed deals will price on potential, not market cap
“Now we are, and this is public in our filing, we are in discussions with potential partners And I think everybody understands that if we're going to do a deal, if we're going to strike a deal, it's not going to be based on the current market cap, but it's goin…”
Assertion Supported
Kidron: Oramed's oral insulin delivery technology was developed by his mother
“So we have a technology that was actually developed by my mother, who is a scientist, that allows us to protect the insulin from degradation, and to take it intact into the liver.”
Disclosure
Kidron: Oramed collected $30M of $50M Chinese licensing deal
“So we got thirty million dollars out of the 50. We should be getting a few more millions this year, and some of it earlier next year as well.”
Disclosure
Kidron: Oramed currently holds about $50M in cash
“The company today is a public company, a NASDAQ. The company, just the cash the company has today, it's about fifty million dollars, five zero, and there's more cash coming from the Chinese.”
Disclosure
Kidron: Over $100M total has gone into Oramed Pharmaceuticals
“Up today, all together, I would say probably over a hundred million dollars of money between the revenues and money was raised, went into the company.”
Disclosure
Kidron: Insiders and Chinese partners own about 50% of Oramed
“Between myself and the Chinese and some of the other shareholders, we own about 50% of the company.”
Disclosure
Oramed is developing oral GLP-1 and leptin candidates alongside insulin
“We have a pipeline. We have other things beyond insulin. So we're working on insulin. We're working on another drug that's called GLP one analog. We're working on leptin.”
Assertion Partly supported
Kidron: China partner invested $12M at double Oramed's market price
“So they did it at about double than what the current market prices. That was at the end of 2015, December, 2015.”
